Drug Profile
Programmed CD34+ cell therapy - Fate Therapeutics
Alternative Names: PD-L1 CD34+ cell therapy - Fate Therapeutics; ToleraCyteLatest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Fate Therapeutics
- Developer Boston Childrens Hospital; Fate Therapeutics
- Class Anti-inflammatories; Antihyperglycaemics; Cell therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Autoimmune disorders in USA (Parenteral) (Fate Therapeutics pipeline, September 2023)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 01 Nov 2017 The US Patent and Trademark Office issues patent covering the use of prostaglandins as viral transduction enhancers for the genetic modification of CD34+ haematopoietic cells